NEWTON, Mass.--(BUSINESS WIRE)--May 22, 2006--Matritech (Amex: MZT - News), a leading developer and marketer of protein-based diagnostic products for the early detection of cancer, announced today that independent investigators have reported that certain tests, such as the NMP22® BladderChek® Test, could save lives and reduce expense when screening high risk populations for bladder cancer.
